EP0687174B1 — Crystalline cyclodextrin inclusion complexes of ranitidine hydrochloride and process for their preparation
Assigned to Hexal AG · Expires 2001-06-13 · 25y expired
What this patent protects
PCT No. PCT/EP94/00645 Sec. 371 Date Dec. 15, 1995 Sec. 102(e) Date Dec. 15, 1995 PCT Filed Mar. 4, 1994 PCT Pub. No. WO94/20091 PCT Pub. Date Sep. 15, 1994The present invention relates to cyclodextrin inclusion complexes of ranitidine hydrochloride which exhibit a novel, to date…
USPTO Abstract
PCT No. PCT/EP94/00645 Sec. 371 Date Dec. 15, 1995 Sec. 102(e) Date Dec. 15, 1995 PCT Filed Mar. 4, 1994 PCT Pub. No. WO94/20091 PCT Pub. Date Sep. 15, 1994The present invention relates to cyclodextrin inclusion complexes of ranitidine hydrochloride which exhibit a novel, to date unknown crystalline structure, being significantly different from those of known "Form 1 and 2" and to the preparation of such inclusion complexes. The inclusion complexes are prepared from aqueous common solution or suspensions of ranitidine hydrochloride and cyclodextrin by removal of water. As complexing agents alpha -, beta - and gamma-cyclodextrins, their alkylated, hydroxy alkylated derivates or their suitable mixtures are utilized. Finally, the invention concerns pharmaceutical compositions comprising the new complexes.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.